97 related articles for article (PubMed ID: 2224850)
21. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
22. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
23. Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70.
Yoshino I; Goedegebuure PS; Peoples GE; Lee KY; Eberlein TJ
J Immunol; 1994 Nov; 153(9):4149-58. PubMed ID: 7930618
[TBL] [Abstract][Full Text] [Related]
24. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
25. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
26. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival.
Barth RJ; Camp BJ; Martuscello TA; Dain BJ; Memoli VA
Cancer; 1996 Sep; 78(6):1168-78. PubMed ID: 8826937
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 activated microglia engulf tumor infiltrating T cells in the central nervous system.
Tamakawa N; Saio M; Suwa T; Ohe N; Yoshimura S; Iwama T; Shinoda J; Sakai N; Takami T
Int J Mol Med; 2004 Apr; 13(4):497-503. PubMed ID: 15010848
[TBL] [Abstract][Full Text] [Related]
28. Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes.
Whiteside TL; Heo DS; Takagi S; Herberman RB
Transplant Proc; 1988 Apr; 20(2):347-50. PubMed ID: 2834838
[TBL] [Abstract][Full Text] [Related]
29. Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor.
Skornick Y; Topalian S; Rosenberg SA
J Biol Response Mod; 1990 Aug; 9(4):431-8. PubMed ID: 2395007
[TBL] [Abstract][Full Text] [Related]
30. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
31. [The motility of IL-2 activated lymphocytes into malignant glioma].
Higa Y; Mukawa J
No To Shinkei; 1992 Sep; 44(9):813-20. PubMed ID: 1476810
[TBL] [Abstract][Full Text] [Related]
32. Extravasation of antitumor effector cells.
Whiteside TL; Herberman RB
Invasion Metastasis; 1992; 12(2):128-46. PubMed ID: 1399401
[TBL] [Abstract][Full Text] [Related]
33. [The antitumor effects of tumor-infiltrating lymphocytes (TIL) being proliferated in vitro].
Zhang BX
Zhonghua Bing Li Xue Za Zhi; 1992 Apr; 21(2):79-81. PubMed ID: 1499075
[TBL] [Abstract][Full Text] [Related]
34. Changes in gravity inhibit lymphocyte locomotion through type I collagen.
Pellis NR; Goodwin TJ; Risin D; McIntyre BW; Pizzini RP; Cooper D; Baker TL; Spaulding GF
In Vitro Cell Dev Biol Anim; 1997 May; 33(5):398-405. PubMed ID: 9196900
[TBL] [Abstract][Full Text] [Related]
35. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.
Risin D; Kleinerman ES; Umezu Y; Pizzini RP; Balch CM; Pellis NR
Cancer Immunol Immunother; 1995 Jan; 40(1):57-64. PubMed ID: 7828168
[TBL] [Abstract][Full Text] [Related]
36. The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity.
Marcus SG; Perry-Lalley D; Mulé JJ; Rosenberg SA; Yang JC
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):105-12. PubMed ID: 8136942
[TBL] [Abstract][Full Text] [Related]
37. The induction of murine tumor infiltrating lymphocytes (TIL) by interleukin-2 or T cell growth factor.
Kan N; Mise K; Nakanishi M; Okino T; Harada T; Ichinose Y; Moriguchi Y; Sugie T; Li L; Imamura M
Biotherapy; 1993; 6(4):303-9. PubMed ID: 8018450
[TBL] [Abstract][Full Text] [Related]
38. Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the alpha1 integrin I-domain.
Ferrero E; Fabbri M; Poggi A; Galati G; Bernasconi S; Zocchi MR
Eur J Immunol; 1998 Aug; 28(8):2530-6. PubMed ID: 9710230
[TBL] [Abstract][Full Text] [Related]
39. Anchorage and lymphocyte function: extracellular matrix substrata control morphogenesis and interleukin production but have minor effects on DNA synthesis.
Sundqvist KG; Pedari L; Hauzenberger D
Scand J Immunol; 1993 Mar; 37(3):295-307. PubMed ID: 8441916
[TBL] [Abstract][Full Text] [Related]
40. The use of transformed T cell lines for clonal expansion of human B cells from peripheral blood, spleen, and tumor-infiltrating lymphocytes.
Barbuto JA; Verastegui EL; Hersh EM
Hybridoma; 1993 Feb; 12(1):115-25. PubMed ID: 8454298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
